Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies

BACKGROUND: Individuals with heterozygous familial hypercholesterolemia (heFH) have higher levels of low-density lipoprotein cholesterol (LDL-C) and are predisposed to premature cardiovascular disease. Alirocumab is a fully-human, monoclonal antibody targeted to proprotein convertase subtilisin/kexi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kastelein, John J. P., Robinson, Jennifer G., Farnier, Michel, Krempf, Michel, Langslet, Gisle, Lorenzato, Christelle, Gipe, Daniel A., Baccara-Dinet, Marie T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074463/
https://www.ncbi.nlm.nih.gov/pubmed/24842558
http://dx.doi.org/10.1007/s10557-014-6523-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074463/
https://www.ncbi.nlm.nih.gov/pubmed/24842558
http://dx.doi.org/10.1007/s10557-014-6523-z

Ejemplares similares